Stay updated on Pembrolizumab and TKI in CML MRD Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and TKI in CML MRD Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision: v3.5.2 has been added, replacing the previous Revision: v3.5.0 on the page.
    Difference
    0.0%
    Check dated 2026-04-16T10:31:02.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    New update dates (e.g., 2026-04-03, 2026-03-31) were added and older dates (e.g., 2026-03-02, 2026-02-27, 2026-02) were removed from the study record.
    Difference
    0.1%
    Check dated 2026-04-09T08:12:55.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    No additions or deletions are visible in the provided data; the page appears unchanged.
    Difference
    0.0%
    Check dated 2026-04-02T00:28:12.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    Screenshot comparison shows no content additions or deletions to core study information. The visible sections appear unchanged, including the brief summary, objectives, and eligibility criteria.
    Difference
    0.0%
    Check dated 2026-03-25T21:00:16.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Revision: v3.5.0 has been added to the page. The previous revision label v3.4.3 has been removed.
    Difference
    0.0%
    Check dated 2026-03-18T18:03:28.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T14:42:56.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and TKI in CML MRD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and TKI in CML MRD Clinical Trial page.